Table 2.
Inhibitory effects of Sc-1, Sc-1bis, Sc-2, Sc-3 and Ga-3 compounds on the VEGF-A165/NRP-1 complex formation in competitive ELISA test (presented as the mean ± SD, n = 3).
| Biomolecule | Sequence | IC50 ± SD | logIC50 ± SD |
|---|---|---|---|
| or Reference Compound | [µM] | ||
| A7R | Ala-Thr-Trp-Leu-Pro-Pro-Arg | 17.47 ± 1.49 | −4.74 ± 0.02 |
| Sc-1 | Sc-DOTA-Ahx-A7R | 22.48 ± 6.56 | −4.65 ± 0.12 |
| Sc-1bis | Lys(DOTA-Sc)-A7R | 18.08 ± 0.46 | −4.74 ± 0.01 |
| K4R | Lys(hArg)-Dab-Pro-Arg | 4.83 ± 0.25 | −5.32 ± 0.12 |
| Sc-2 | Sc-DOTA-Ahx-K4R | 17.93 ± 1.80 | −4.73 ± 0.03 |
| DR7A | dArg-dPro-dPro-dLeu-dTrp-dThr-dAla | >100 | n/a |
| Ga-3 | DR7A-DLys(DOTA-Ga) | >100 | n/a |
| Sc-3 | DR7A-DLys(DOTA-Sc) | >100 | n/a |